Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
OBSVF similar filings
- 10 Mar 22 ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
- 10 Feb 22 ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
- 4 Feb 22 ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
- 1 Feb 22 ObsEva Appoints Katja Buhrer as Chief Strategy Officer
- 28 Jan 22 ObsEva Announces Corporate Updates
- 6 Jan 22 ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
- 17 Dec 21 ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Filing view
External links